Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey


BEKSAÇ M., Seval G. C. , PAYDAŞ S. , Tuglular T. F. , ARSLAN Ö., GÖKER H., ...Daha Fazla

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.19, 2019 (SCI İndekslerine Giren Dergi) identifier

  • Cilt numarası: 19 Konu: 10
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.clml.2019.09.402
  • Dergi Adı: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA